Acurx Pharmaceuticals (ACXP) Announces Successful FDA End-of

Acurx Pharmaceuticals (ACXP) Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection

Acurx Pharmaceuticals (ACXP) Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Robertj Deluccia , , Trial Oversight Committee , Nasdaq , Drug Administration , Data Monitoring Committee , Acurx Pharmaceuticals Inc , Company Scientific Advisory Board , Acurx Pharmaceuticals , Advice Meeting , Modified Intent To Treat , Clinical Cure , Executive Chairman , New Drug Application , Marketing Authorizations , Ibezapolstat Phase , Scientific Advisory Board , Modified Intent , Treat Population , Per Protocol Population , Prescribing Information , Independent Data Monitoring Committee , Fast Track Designated , Gram Positive Selective Spectrum , Qualified Infectious Disease Product , Generating New Antibiotic Incentives Now ,